

Chemistree Investee - ImmunoFlex Receives NRC IRAP Funding

VANCOUVER, BC, Feb. 8, 2021 /CNW/ - Chemistree Technology Inc. (CSE: CHM) (CSE: CHM.WT) (OTCQB: CHMJF) (the "Company" or "Chemistree") is pleased to inform shareholders that Chemistree investee ImmunoFlex™ has today announced that it is receiving advisory services and conditional research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).

"ImmunoFlex is now recruiting patients into a Phase 4 clinical trial designed to optimize the impact of FLEX 20™ on the immune system. The funding from NRC IRAP will support a project focused on analyzing immune system data collected from this clinical trial," said ImmunoFlex CEO Chris Wagner. We are grateful for their support."

"On behalf of Chemistree shareholders and the Board of Directors, I am happy to congratulate Chris and his team on achieving support from NRC IRAP. This is a significant milestone for Immunoflex and we are looking forward to further developments soon. I also encourage CHM shareholders to sign up for the FLEX 10™ Early Access Program and learn more about Immunoflex and its growing product lines." commented Chemistree President Karl Kottmeier.

About FLEX 10™

FLEX 10™ is ImmunoFlex's unique 600mg N-Acetyl-L-cysteine formulation in packs of 30 capsules. FLEX 10™ is a powerful antioxidant, specifically packaged in aluminum foil blisters to reduce the potential for product oxidation. To sign up for the FLEX 10™ Early Access Program, send an e-mail to info@immunoflex.com.

About FLEX 20™

FLEX 20™ is ImmunoFlex's patent-pending combination of natural health products targeted at measurably enhancing the immune system. ImmunoFlex is currently conducting a Phase 4 clinical trial to optimize FLEX 20™.

About ImmunoFlex™

ImmunoFlex™ works with the immune system to strengthen, support, and enhance our body's natural surveillance and response system. By combining natural health products with pharmaceutical-grade ingredients and genomics we create patented, premium, immune-boosting products. Learn more at www.immunoflex.com

Forward Looking Statements

This press release contains forward-looking statements about ImmunoFlex's objectives, strategies and tactics that involve risks and uncertainties. These statements are "forward-looking" as they are based on our current expectations about the markets we operate in and on various assumptions and estimates. Actual results or events may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.

Learn more at www.immunoflex.com

About Chemistree Technology Inc.

Chemistree Technology Inc. is an investment company with holdings in the U.S. cannabis sector, real estate, and a consumer-targeted biotechnology venture. The Company's corporate strategy is to focus on opportunistic investments across a broad range of industries, and is seeking to invest in early stage, promising companies where it may be the lead investor and can additionally provide investees with advisory services, mentoring and access to the Company's management expertise. For more information, visit www.Chemistree.ca.

Advisory

The Company wishes to inform shareholders that there are significant legal restrictions and regulations that govern the cannabis industry in both Canada and the United States.

Cannabis-related Practices or Activities are Illegal Under U.S. Federal Laws

The concepts of "medical cannabis" and "recreational cannabis" do not exist under U.S. federal law. The Federal Controlled Substances Act classifies "marihuana" as a Schedule I drug. Under U.S. federal law, a Schedule I drug or

substance has a high potential for abuse, no accepted medical use in the United States, and a lack of safety for the use of the drug under medical supervision. As such, cannabis related practices or activities, including without limitation, the manufacture, importation, possession, use or distribution of cannabis are illegal under U.S. federal law. Strict compliance with state laws with respect to cannabis will neither absolve the Company of liability under U.S. federal law, nor will it provide a defence to any federal proceeding which may be brought against the Company. Enforcement of U.S. federal laws will be a significant risk to the business of the Company and any such proceedings brought against the Company may adversely affect the Company's operations and financial performance.

Further information regarding the legal status of cannabis related activities and associated risk factors, including, but not limited to, risk of enforcement actions, risks that third-party service providers, such as banking or financial institutions cease providing services to the Company, and the risk that Company may not be able to distribute profits, if any, from U.S. operations up to the Company, are included in the Prospectus, the Company's annual information form and other documents incorporated by reference therein and in the Company's Form 2A listing statement filed with the CSE and available under the Company's profile on SEDAR at www.sedar.com.

"Karl Kottmeier"

President

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Information set forth in this news release includes forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as "anticipate", "believe", "plan", "estimate", "expect", "budget", "scheduled" and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions.

By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the risks identified in the Company's reports and filings with the applicable Canadian securities regulators. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made, and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law.

View original content to download multimedia:

<http://www.prnewswire.com/news-releases/chemistree-investee---immunoflex-receives-nrc-irap-funding-301224095.html>

SOURCE Chemistree Technology Inc.

View original content to download multimedia:

<http://www.newswire.ca/en/releases/archive/February2021/08/c4912.html>

%SEDAR: 00027350E

For further information: Chemistree Technology Inc., Karl Kottmeier, President, Phone: 604-678-8941, Email: info@Chemistree.ca; For investor relations please contact: Contact Financial Corp., Kirk Gamley, Phone: 604-689-7422, Email: kirk@contactfinancial.com

CO: Chemistree Technology Inc.

CNW 12:41e 08-FEB-21